Fox Run Management’s Agios Pharmaceuticals AGIO Stock Holding History

Fox Run Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$580K	Buy	+15,622	New	+$474K	0.1%	414
2026 Q1	–	Sell	-12,567	Closed	-$342K	–	871
2025 Q4	$342K	Buy	+12,567	New	+$441K	0.05%	650
2025 Q3	–	Sell	-17,707	Closed	-$589K	–	880
2025 Q2	$589K	Buy	+17,707	New	+$537K	0.1%	397
2025 Q1	–	Sell	-23,839	Closed	-$783K	–	881
2024 Q4	$783K	Buy	+23,839	New	+$1.12M	0.14%	255
2024 Q3	–	Sell	-6,818	Closed	-$294K	–	772
2024 Q2	$294K	Buy	+6,818	New	+$246K	0.06%	560
2019 Q1	–	Sell	-5,542	Closed	-$256K	–	442
2018 Q4	$256K	Buy	+5,542	New	+$342K	0.14%	320
2018 Q3	–	Sell	-8,707	Closed	-$733K	–	549
2018 Q2	$733K	Buy	8,707 +3,833	+79%	+$334K	0.23%	121
2018 Q1	$399K	Buy	+4,874	New	+$377K	0.1%	392
2017 Q4	–	Sell	-8,600	Closed	-$574K	–	646
2017 Q3	$574K	Buy	+8,600	New	+$517K	0.16%	241
2017 Q1	–	Sell	-5,600	Closed	-$234K	–	550
2016 Q4	$234K	Buy	+5,600	New	+$294K	0.12%	380

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Fox Run Management's AGIO Position: Q2 2026 in Review

Fox Run Management opened a new position in Agios Pharmaceuticals (AGIO) in Q2 2026: 15,622 shares worth $580K. The stake represents 0.1% of the portfolio and ranks #414 among its holdings. This is a return to the name: Fox Run Management previously reported a position in AGIO as recently as Q4 2025.

Fox Run Management first reported a position in AGIO in Q4 2016 and has held it in 10 quarters since. The position peaked at $783K in Q4 2024. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Fox Run Management held 15,622 shares of Agios Pharmaceuticals worth $580K as of Q2 2026.
Agios Pharmaceuticals was a new Fox Run Management position in Q2 2026.
Agios Pharmaceuticals made up 0.1% of Fox Run Management's portfolio in Q2 2026, its #414 holding.
Fox Run Management first reported a position in Agios Pharmaceuticals in Q4 2016 and has held it in 10 quarters since.
Fox Run Management's Agios Pharmaceuticals position peaked at $783K in Q4 2024.
239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.